Scholar Rock's ISEMBYLD wins FDA approval for spinal muscular atrophy treatment
On September 11, 2026, Scholar Rock Holding Corporation announced that the FDA approved ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy in adults and children 2 years of age and older who are receiving an SMN2-targeted treatment. The company said the U.S. commercial launch is underway, with product available to ship in the coming days, and it received a Rare Pediatric Disease Priority Review Voucher with the approval.
Key points
- Phase 3 SAPPHIRE study: 2.2-point HFMSE motor function improvement vs. placebo at one year (nominal p=0.0121)
- 34.2% of ISEMBYLD-treated patients showed a 3-point or greater HFMSE increase vs. 13.5% on placebo
- Fractures occurred in 9% of ISEMBYLD 10 mg/kg patients vs. 2% on placebo; the label notes an increased fracture risk
- Management webcast and conference call on September 14, 2026, at 8:00 a.m. ET; cash and securities were $492 million as of June 30, 2026
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.